Suppliers and packagers for generic pharmaceutical drug: SALMETEROL XINAFOATE

SALMETEROL XINAFOATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Glaxosmithkline	SEREVENT	salmeterol xinafoate	POWDER;INHALATION	020692	NDA	GlaxoSmithKline LLC	0173-0521-00	1 INHALER in 1 CARTON (0173-0521-00) / 60 POWDER, METERED in 1 INHALER	1997-11-25

Salmeterol Xinafoate Supply Chain Analysis

Last updated: February 19, 2026

This report details the current landscape of suppliers for Salmeterol Xinafoate, a long-acting beta-agonist (LABA) bronchodilator used in the management of asthma and chronic obstructive pulmonary disease (COPD). The analysis focuses on active pharmaceutical ingredient (API) manufacturers and key intermediates, assessing their production capabilities, geographic distribution, and regulatory standing.

Who are the primary API manufacturers for Salmeterol Xinafoate?

The production of Salmeterol Xinafoate API is concentrated among a limited number of manufacturers globally. Key players are located in India and China, leveraging cost advantages and established chemical synthesis infrastructure.

Major API Suppliers:

• Dr. Reddy's Laboratories Ltd.
  • Location: India
  • Known for significant API manufacturing capacity across various therapeutic areas, including respiratory.
  • Regulatory Filings: Holds multiple Drug Master Files (DMFs) with regulatory agencies like the US FDA.
• Lupin Ltd.
  • Location: India
  • A prominent pharmaceutical company with substantial API production, including respiratory APIs.
  • Regulatory Filings: Maintains a strong portfolio of DMFs and CEPs (Certificates of Suitability to the monographs of the European Pharmacopoeia).
• Sun Pharmaceutical Industries Ltd.
  • Location: India
  • One of the largest generic pharmaceutical companies, with extensive API manufacturing operations.
  • Regulatory Filings: Possesses numerous DMFs and has a history of successful regulatory inspections.
• Cipla Ltd.
  • Location: India
  • A long-standing player in the respiratory space, with established API manufacturing.
  • Regulatory Filings: Holds DMFs and has a global presence in API supply.
• Divi's Laboratories Ltd.
  • Location: India
  • Specializes in custom synthesis and the manufacture of APIs, including complex molecules.
  • Regulatory Filings: Known for its robust manufacturing infrastructure and compliance.
• Various Chinese Manufacturers
  • While specific company names often fluctuate or operate under custom synthesis agreements, China represents a significant source of API production for Salmeterol Xinafoate and its intermediates. These suppliers are critical for cost-competitive sourcing.
  • Regulatory Filings: Many Chinese API manufacturers have obtained DMFs or are in the process of securing them, catering to international markets.

These manufacturers vary in their capacity, lead times, and pricing, necessitating careful selection based on project requirements and risk tolerance.

What are the key intermediates in Salmeterol Xinafoate synthesis, and who supplies them?

The synthesis of Salmeterol Xinafoate involves several complex chemical steps, with specific intermediates being crucial for efficient and high-quality production. The supply chain for these intermediates is equally important.

Critical Intermediates and Suppliers:

• 4-Hydroxy-3-(hydroxymethyl)phenylacetic acid derivatives: This class of compounds serves as a foundational building block.
  • Suppliers: A mix of specialized chemical manufacturers in India, China, and some European countries. These are often custom-synthesized or produced by companies focusing on advanced intermediates.
• 4-(Hydroxymethyl)-2-(4-phenylbutoxy)phenol derivatives: This intermediate incorporates a significant portion of the Salmeterol molecule's structure.
  • Suppliers: Similar to the phenylacetic acid derivatives, these are typically sourced from specialized fine chemical producers. Contract Manufacturing Organizations (CMOs) play a significant role in producing these in bulk.
• Xinafoic Acid (1-hydroxy-2-naphthoic acid): This acid is paired with Salmeterol to form the salt.
  • Suppliers: Xinafoic acid is a more common chemical commodity, with multiple suppliers globally, including manufacturers in China and India. Quality and purity are paramount for pharmaceutical grade material.

The sourcing of these intermediates often involves a tiered supply chain, where API manufacturers may source directly from intermediate producers or rely on distributors and CMOs. The geographical concentration of intermediate production, particularly in Asia, presents both opportunities for cost savings and potential risks related to supply chain disruptions.

What is the regulatory landscape for Salmeterol Xinafoate API manufacturing?

Compliance with stringent regulatory requirements is a prerequisite for API manufacturers supplying to regulated markets like the United States, Europe, and Japan. Key regulatory aspects include Good Manufacturing Practices (GMP), Drug Master Files (DMFs), and Certificates of Suitability (CEPs).

Key Regulatory Considerations:

• US Food and Drug Administration (FDA):
  • GMP Compliance: Facilities must adhere to 21 CFR Part 210 and 211.
  • DMF Filings: Manufacturers submit Type II DMFs detailing the manufacturing process, quality control, and stability of the API. These DMFs are reviewed by the FDA as part of new drug applications (NDAs) or abbreviated new drug applications (ANDAs).
  • Facility Inspections: API manufacturing sites are subject to FDA inspections to verify GMP compliance.
• European Medicines Agency (EMA) & National Competent Authorities:
  • GMP Compliance: Facilities must comply with EudraLex Volume 4.
  • CEP (Certificate of Suitability to the monographs of the European Pharmacopoeia): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), a CEP certifies that an API complies with the relevant European Pharmacopoeia monograph. This simplifies the regulatory process for marketing authorization applications in Europe.
  • Site Master Files (SMFs): These provide detailed information about the manufacturing facilities.
• Other Regulatory Bodies: Manufacturers targeting other markets must comply with local regulatory requirements, such as those in Japan (PMDA), Canada (Health Canada), and Australia (TGA).

Data on Regulatory Filings:

• US FDA DMFs: A review of publicly available FDA DMF data indicates that several Indian manufacturers, including Dr. Reddy's Laboratories, Lupin, and Sun Pharma, have active DMFs for Salmeterol Xinafoate. The specific number of active DMFs can fluctuate as new applications are submitted and older ones are updated or become inactive.
• EDQM CEPs: Companies like Cipla and Lupin have obtained CEPs for Salmeterol Xinafoate API, facilitating its use in European markets. The EDQM database can be consulted for current CEP holders.

The reliance on a limited number of regulatory-approved sites underscores the importance of maintaining robust quality systems and proactive engagement with regulatory authorities.

What are the geographical concentrations and potential supply chain risks?

The global supply chain for Salmeterol Xinafoate API and its intermediates is heavily concentrated in Asia, primarily India and China. This concentration offers economic advantages but also introduces significant supply chain risks.

Geographic Distribution of Key Suppliers:

• API Manufacturing: Over 70% of global Salmeterol Xinafoate API manufacturing capacity is estimated to be in India. China accounts for a substantial portion of the remaining capacity, often for cost-driven markets or as secondary suppliers.
• Intermediate Manufacturing: The production of key chemical intermediates is also predominantly located in India and China, with some specialized capabilities in Europe.
• Finished Dosage Form (FDF) Manufacturing: While API is concentrated, FDF manufacturing for inhaled products using Salmeterol Xinafoate (e.g., Diskus devices, metered-dose inhalers) is more geographically diversified, with significant players in the US, Europe, and India.

Potential Supply Chain Risks:

• Geopolitical Instability: Tensions or conflicts in key manufacturing regions could disrupt production and logistics.
• Natural Disasters: Earthquakes, floods, or pandemics in India or China could halt manufacturing operations.
• Regulatory Changes: Stricter environmental regulations or export/import policies in manufacturing countries can impact supply.
• Quality and Compliance Issues: Any significant GMP non-compliance or quality recall at a major API supplier can have a widespread impact on the global supply of Salmeterol Xinafoate.
• Logistical Challenges: Shipping delays, port congestion, or increased freight costs can affect lead times and overall costs.
• Intellectual Property (IP) Protection: While Salmeterol is off-patent for the molecule itself, patent protection on specific polymorphic forms, manufacturing processes, or drug delivery devices can still influence market dynamics and supplier options.

Mitigation Strategies:

• Dual Sourcing: Engaging with multiple qualified API manufacturers and intermediate suppliers.
• Geographic Diversification: Where feasible, seeking suppliers in different regions to reduce single-point-of-failure risks.
• Supply Chain Audits: Conducting regular and thorough audits of all critical suppliers.
• Inventory Management: Maintaining adequate safety stocks of API and critical intermediates.
• Contractual Safeguards: Including clauses in supply agreements that address business continuity and force majeure events.

How do API costs compare across key suppliers?

API costs for Salmeterol Xinafoate are influenced by manufacturing scale, regulatory compliance investments, labor costs, raw material prices, and market competition. Indian manufacturers generally offer more competitive pricing due to lower operational costs and large-scale production.

Estimated Cost Ranges (USD per Kilogram):

• Tier 1 Indian Manufacturers (High Volume, Established Compliance): \$250 - \$450
• Tier 2 Indian Manufacturers & Chinese Manufacturers (Competitive Pricing): \$180 - \$300
• European/US Specialized Manufacturers (Niche/Custom Synthesis): \$400 - \$700+ (less common for bulk generic API)

These figures are indicative and can vary significantly based on contract terms, order volume, and the specific quality grade and specifications required. Price negotiations are a critical aspect of procurement for generic drug manufacturers. The introduction of new generics or changes in demand patterns can also impact pricing dynamics.

Key Takeaways

• The global supply of Salmeterol Xinafoate API is dominated by manufacturers in India, with significant contributions from China.
• Key intermediates in the synthesis also have a concentrated supply base in Asia, posing potential supply chain risks.
• Regulatory compliance, particularly US FDA GMP and EMA CEPs, is a critical factor for market access and supplier selection.
• Geopolitical factors, natural disasters, and quality control issues represent significant risks to the supply chain due to geographical concentration.
• API costs are generally lower from Indian manufacturers, reflecting operational cost advantages and economies of scale.

Frequently Asked Questions

1. What are the typical lead times for Salmeterol Xinafoate API orders? Lead times can range from 8 to 16 weeks, depending on the manufacturer's current production schedule, order volume, and raw material availability. Rush orders may incur additional costs and are subject to availability.

2. Are there any emerging suppliers of Salmeterol Xinafoate API? While the market is established, new players, particularly from China, may enter the market or increase their capacity. However, gaining regulatory approvals (FDA DMF, CEP) is a lengthy and costly process, acting as a barrier to entry for truly novel suppliers.

3. What is the impact of patent expiries on Salmeterol Xinafoate API sourcing? The molecule itself is off-patent, allowing for generic API production. However, patents related to specific polymorphic forms, manufacturing processes, or novel drug delivery systems can still influence market access and competition for finished products, indirectly affecting API demand and supplier relationships.

4. How does the purity specification of Salmeterol Xinafoate API vary between suppliers? All reputable API manufacturers must adhere to pharmacopoeial standards (e.g., USP, EP, JP) for purity. Variations typically lie in the impurity profiles beyond pharmacopoeial limits, specific polymorphic forms, particle size distribution, and residual solvent levels, which are critical for formulation into specific inhalation devices.

5. What are the implications of single-source vs. multi-source API strategies for Salmeterol Xinafoate? A single-source strategy can lead to stronger supplier relationships and potential volume discounts but exposes companies to significant supply chain disruption risks. A multi-source strategy mitigates these risks but requires managing multiple supplier relationships, qualifying additional manufacturers, and potentially higher initial procurement costs.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from www.fda.gov [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability (CEP). Retrieved from www.edqm.eu [3] U.S. Pharmacopeia. (n.d.). United States Pharmacopeia–National Formulary (USP-NF). [4] European Pharmacopoeia. (n.d.). European Pharmacopoeia (Ph. Eur.). [5] Industry market research reports on pharmaceutical APIs (specific titles and publishers vary and are proprietary).